Lupin receives FDA nod for 2 generics

Lupin has received the FDA’s nod for Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device), which is a generic of Par’s Nascobal.

Nascobal is a vitamin B12 supplement. 

The product will be manufactured at Lupin’s Somerset facility in the United States.

Cyanocobalamin Nasal Spray had a market value of roughly $69 million, per IQVIA March 2023 data.

[Read more: FDA approves 3 Lupin generics]

Lupin also received the FDA’s permission for Dolutegravir tablets for oral suspension, 5 mg, which is a generic of ViiV Healthcare’s Tivicay.

Tivicay is used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

The product will be manufactured at Lupin’s Nagpur facility in India.

[Read more: Lupin launches generic Banzel]

Dolutegravir tablets for oral suspension had a market value of approximately $1 million, per IQVIA March 2023 data.